Lasmecabtagene Timgedleucel

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of allogeneic, off-the-shelf (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human CD22 with potential immunomodulating and antineoplastic activities. Upon transfusion, lasmecabtagene timgedleucel bind to the CD22 antigen on tumor cell surfaces, resulting in lysis of CD22-expressing tumor cells. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells.

**Synonyms:** - Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22 - Allogeneic Gene-edited CAR T-Cells UCART22 - Allogeneic TALEN Gene-edited CAR T-Cells UCART22 - Allogenic Engineered T-cells Expressing Anti- CD22 CAR UCART22 - LASMECABTAGENE TIMGEDLEUCEL - Lasme-cel - UCART 22 - UCART-22 - UCART22 - UCART22 Cells